The antiserum was produced against synthesized peptide derived from human CCR5 around the phosphorylation site of Ser349. AA range:303-352

Phospho-CCR5 (S349) Polyclonal Antibody detects endogenous levels of CCR5 protein only when phosphorylated at S349.The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):EIsVG

CCR5

C-C chemokine receptor type 5

CCR5 ;
CMKBR5 ;
C-C chemokine receptor type 5 ;
C-C CKR-5 ;
CC-CKR-5 ;
CCR-5 ;
CCR5 ;
CHEMR13 ;
HIV-1 fusion coreceptor ;
CD antigen CD195

This gene encodes a member of the beta chemokine receptor family, which is predicted to be a seven transmembrane protein similar to G protein-coupled receptors. This protein is expressed by T cells and macrophages, and is known to be an important co-receptor for macrophage-tropic virus, including HIV, to enter host cells. Defective alleles of this gene have been associated with the HIV infection resistance. The ligands of this receptor include monocyte chemoattractant protein 2 (MCP-2), macrophage inflammatory protein 1 alpha (MIP-1 alpha), macrophage inflammatory protein 1 beta (MIP-1 beta) and regulated on activation normal T expressed and secreted protein (RANTES). Expression of this gene was also detected in a promyeloblastic cell line, suggesting that this protein may play a role in granulocyte lineage proliferation and differentiation. This gene is located at the chemok

Disease:Genetic variation in CCR5 is associated with suseptibility to insulin-dependent diabetes mellitus type 22 (IDDM22) [MIM:612522]. IDDM is caused by the body's own immune system which destroys the insulin-producing beta cells in the pancreas. Classical features are polydipsia, polyphagia and polyuria, due to hyperglycemia-induced osmotic diuresis.,Function:Receptor for a number of inflammatory CC-chemokines including MIP-1-alpha, MIP-1-beta and RANTES and subsequently transduces a signal by increasing the intracellular calcium ion level. May play a role in the control of granulocytic lineage proliferation or differentiation. Acts as a coreceptor (CD4 being the primary receptor) for HIV-1 R5 isolates.,online information:CC chemokine receptors entry,online information:CCR5 receptor entry,polymorphism:Ser-60 variant, a naturally occurring mutation in a conserved residue in the first intracellular domain of CCR5, results in reduced amounts of the protein in the membrane and consequently may be associated with reduced susceptibility to infection by microbes that depend on these molecules as their receptors.,polymorphism:Variations in CCR5 are associated with resistance or susceptibility to immunodeficiency virus type 1 (resistance or susceptibility to HIV-1) [MIM:609423]. Variations in CCR5 gene also influence the rate of progression to AIDS after infection.,polymorphism:Variations in CCR5 are associated with susceptibility to West Nile virus (WNV) infection [MIM:610379].,PTM:O-glycosylated, but not N-glycosylated. Ser-6 appears to be the major site. Also sialylated glycans present which contribute to chemokine binding. Thr-16 and Ser-17 may also be glycosylated and, if so, with small moieties such as a T-antigen.,PTM:Palmitoylation in the C-terminal is important for cell surface expression, and to a lesser extent, for HIV entry.,PTM:Phosphorylation on serine residues in the C-terminal is stimulated by binding CC chemokines especially by APO-RANTES.,PTM:Sulfated on at least 2 of the N-terminal tyrosines. Sulfation contributes to the efficiency of HIV-1 entry and is required for efficient binding of the chemokines, CCL3 and CCL4.,similarity:Belongs to the G-protein coupled receptor 1 family.,subunit:Interacts with PRAF2. Interacts with HIV-1 surface protein gp120. Efficient ligand binding to CCL3/MIP-1alpha and CCR4/MIP-1beta requires sulfation, O-glycosylation and sialic acid modifications. Glycosylation on Ser-6 is required for efficient binding of CCL4. Interacts with ADRBK1.,tissue specificity:Highly expressed in spleen, thymus, in the myeloid cell line THP-1, in the promyeloblastic cell line KG-1A and on CD4+ and CD8+ T-cells. Medium levels in peripheral blood leukocytes and in small intestine. Low levels in ovary and lung.,

Cell membrane ; Multi-pass membrane protein .

>>Viral life cycle - HIV-1 ;
>>Cytokine-cytokine receptor interaction ;
>>Viral protein interaction with cytokine and cytokine receptor ;
>>Chemokine signaling pathway ;
>>Endocytosis ;
>>Toxoplasmosis ;
>>Human cytomegalovirus infection ;
>>Kaposi sarcoma-associated herpesvirus infection ;
>>Human immunodeficiency virus 1 infection ;
>>Viral carcinogenesis